The purpose of the study is to analyze the changes in the ambulatory pharmacotherapy cost of kidney transplant patients in Bulgaria during the years 2006-2011 and the factors influencing it. It is a prospective cost study of changes in ambulatory pharmacotherapy cost. The cost of pharmacotherapy was calculated per patient per year and per month on average. In total, 21 therapeutic schemes were prescribed for 589 individuals per year on average. Most often, the prescribed therapeutic scheme was ciclosporin + mycophenolate, 38% to 39% of all cases during 2006 and 2011 respectively. Average cost of therapy differs in great interval and depends on age of the patients, place of transplantation, life with the graft, development of the citomegalovirus infection etc. Our study shows that the average monthly cost of pharmacotherapy decreases during 2006-2011, as a result of introduction of generic immune suppressors. All evaluated factors influence the statistically significant cost of pharmacotherapy.
Introduction
Renal transplantation is considered as successful therapy for chronic kidney disease [1] . After the transplantation, a life time pharmacotherapy with immunosuppressors [2] is necessary. Contemporary immunosuppressive therapy includes calcineurin inhibitors (CI), or cyclosporin, or tacrolimus, combined with at least one more medicine [3, 4] . There are published evidences that the introduction of new immune suppressors increases the cost of pharmacotherapy, but maintains the graft longevity, improves quality of life and increases survival [3, 5] .
The cost of renal transplantation is widely studied from a national perspective [6] [7] [8] [9] . There are a limited number of studies on the cost of immunosuppressive pharmacotherapy at a national level and the factors affecting it. This stimulates our interest towards this topic [10, 11] .
The purpose of the study is to analyze the changes in the ambulatory pharmacotherapy cost of kidney transplant patients in Bulgaria during the years 2006-2011 and the factors influencing it.
We have explored several study questions: 1) What is the average monthly and yearly pharmacotherapy cost for kidney transplant patients?
2) Are there statistically significant differences in pharmacotherapy cost during the years and among different patients groups?
3) Which factors influence the pharmacotherapy cost?
Methods
It is a prospective cost study of changes in ambulatory pharmacotherapy cost for all adult patients in Bulgaria during the period 2006-2011. On total 598 adult patients were included in the study.
about the prescribed medicines was collected on a monthly basis, changes in pharmacotherapy, new medicines introduction, addition of therapy for citomegalo virus infections and other patients' characteristics. The cost of pharmacotherapy was calculated per patient per year and per month on average.
All costs are presented in national currency Bulgarian leva (BGN) at the ex-change rate of 1 Euro = 1.95 BGN. Descriptive statistic, t-tests analyses were performed to evaluate the changes in the prescribing practice and cost of pharmacotherapy.
The regression analytical model "Curve estimation" was also used to test the relation between the cost of pharmacotherapy and patients' transplantation age, as well as between the pharmacotherapy cost and number of years after transplantation.
The analysis was done with the IBM SPSS Statistics 19.0. Kidney transplant patients are usually treated with different immune suppressors as mono therapy or in combination. On total 21 therapeutic schemes were found prescribed ( Table 1) . The number of patients on therapy during the years differs and it is also lower than all observed 589 individuals because some patients dropping out due to graft rejection. Most often, the prescribed therapeutic scheme was ciclosporin + mycophenolate; 38% to 39% of all cases during 2006 and 2011 respectively. Sodium and mofetil salts of mycophenolate are considered as the same product. Second most often prescribed was the combination of cyclosporine + azathioprine in 48% to 18% of all cases with decreasing frequency. After the introduction of tacrolimus in 2008 its inclusion into the therapeutic schemes started to increase especially in combination with mycophenolate. Until 2011 only 19% of patients were prescribed that particular combination. All patients using micophenolate were aditionally prescribed corticosteroids, while for the other patients-only in case of necessity. The risk of graft rejection was managed with thymoglobulin, HBV infection was treated with lamivudine, and cytomegalovirus infection-with gancyclovir.
Results

385
Average monthly cost of pharmacotherapy was varying among patients and years. An initial increase in the average monthly cost was observed from 2007 to 2009 after which the cost started to decrease. Almost all the changes in the average monthly cost were found to be statistically significant (p < 0.05)- Table 2 . The descrip- tive statistics shows that there is no constant average monthly cost of pharmacotherapy. It varies in a great range from 0 to 2800 BGN. Detailed analysis of the changes in the prescribing and pharmacotherapy cost revealed that n = 291 were on therapy during the whole observed period of 6 years- Table 3 . Out of all 598 observed from 412 to 473 were on therapy yearly, which means that around 20% dropped out. No statistically significant difference was found regarding the cost of pharmacotherapy and patients gender.
The question for patients' age at the moment of transplantation is important because older patients could have more damaged organs thus making the transplantation riskier. It could also affect the pharmacotherapy cost. By using the regression analysis was explored the relation mong the cost of pharmacotherapy and patients' transa Expenses-the average monthly pharmacotherapy cost during 6 years; age of transplantation-patient age at the moment of transplantation.
Negative relation means that with the increase of patients' age when the transplantation is done the pharmacotherapy cost decreases. The calculated with the model decrease is with 2.1 monetary units.
Another explored relation is that among the pharmacotherapy cost and number of years after transplantation. This relation could be described with a cubic model (p < 0.001, R 2 = 0.140) with the following parameters: Years AT-years after transplantation. Graphically, the model is shown on Figure 2 . During the first 8 years after the transplantation the cost increases, then following a 10 year decrease period begins to increase again.
The development of the citomegalovirus infection is a common complication which increases the probability of graft rejection. Table 4 shows the average 6 years pharmacotherapy cost for patients with and without citomegalovirus infections. Patients with infections possess higher cost of pharmacotherapy and the difference is statistically significant.
Due to the important effect on pharmacotherapy cost of CMV-infections other possible factors that could lead to their development were analyzed. The frequency of the CMV infection was found to depend on the country where the transplantation was made. Out of all 19 countries only Pakistani transplanted patients (n = 69) developed statistically significant CMV-infections at a greater frequency (p < 0.01).
Patients' age at the moment of transplantation did not influence the CMV-infection frequency but in general patients less than 30 years of age have more CMV infections than other patients (p < 0.05).
Discussion
To our knowledge this is the first Bulgarian study of prescribing practice and changes in pharmacotherapy cost of kidney transplant patients. In contrast with other countries all kidney transplant patients in Bulgaria receive standard pharmacotherapy that is 100% reimbursed despite of the fact that they might be transplanted in other country as is the case for lots of patients [12] [13] [14] . All of the contemporary immune suppressors were prescribed in the kidney transplant patients. The prescribing is similar with the reported practice in other studies [10, 11] .
Our study shows that the average monthly cost of pharmacotherapy decreases during 2006-2011. This could be explained partly with the introduction of three generic version of the most often prescribed medicines (azathioprid, mycophenolate mofetil and ciclosporin). It leads to price reduction and thus influences the pharmacotherapy cost.
Three other major drivers of the pharmacotherapy cost are patients' age and CMV-infections, as well as the place of transplantation. Patients age influence the cost negatively that could be explained with the decrease in the average daily dose of the immune suppressors. The dose decrease is a common practice that is used to increase patients' compliance and therapy intensity during the years [15] . On the other hand, the age when the transplantation was done influenced the cost of therapy positively as was shown also from other studies [16] [17] [18] . The CMV-infections logically increase the cost due to the addition of one more medicine to the standard immune suppression.
The created regression models provide us with the opportunity to analyze future tendencies in the cost of pharmacotherapy and thus to select group of patients with expected changes in pharmacotherapy cost. We did expect that the patients older than 55 years at the moment of transplantation will have higher pharmacotherapy cost but this was not the case. The only logical explanation could be the dosage decrease performed to protect patients' immunity, as was explained above, but this idea needs further analysis. The second regression model revealed that for the patients living with graft more than 18 years an increase in the pharmacotherapy cost could be expected. This could be used by reimbursing institutions for budget purposes.
Conclusion
Pharmacotherapy cost of kidney transplant patients in Bulgaria is decreasing as a result of introduction of generic immune suppressors. Important factors influencing pharmacotherapy cost are patients' age at the moment of transplantation, country of transplantation, generic medicines introduction and CMV infections. Those factors influence the statistically significant cost of pharmacotherapy.
